Futura Medical's (LON:FUM) James Barder speaks to Proactive London's Andrew Scott following the news they've completed initial laboratory and optimisation work on its Dermasys® cannabidiol gel (CBD100). He says the studies have demonstrated highly efficient penetration of cannabidiol into and through the skin and that the results have shown its superiority to an established, marketed, comparator product. Barder adds they've now started to explore commercialisation options for CBD100.
04 Aug 20